Bowen Acquisition is a special purpose acquisition company (SPAC) formed to complete a merger, share exchange, asset acquisition, or similar business combination with an operating company. Bowen has no commercial operations and generates no operational revenue. The company's business model centers on holding proceeds from its IPO in a trust account, earning interest while searching for and completing a transaction with a private operating business. Public shareholders maintain the right to redeem their shares for their pro-rata portion of the trust account before a business combination is completed. Sponsors hold founder shares that gain value only upon a completed acquisition. Bowen has entered into a merger agreement to combine with Shenzhen Qianzhi BioTechnology, a biotechnology company based in China. If the transaction closes, Qianzhi will become Bowen's operating business. If the merger fails to close, Bowen must complete an alternative business combination or liquidate the trust account and return the remaining capital to public shareholders.